# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $7 price target.
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.02) per share.
Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and maintains $7 p...
Leerink Partners analyst Joseph Schwartz maintains Mereo BioPharma Group (NASDAQ:MREO) with a Outperform and raises the pric...
Baird analyst Jack Allen initiates coverage on Mereo BioPharma Group (NASDAQ:MREO) with a Outperform rating and announces P...